INTRODUCTION *
Bacterial infections, caused by Gram-positive and -negative pathogens, are capable of leading various serious and even fatal diseases both in hospital and in the community. 1 Bacteria resistance to antibiotics which is associated with considerable mortality poses one of major threats to global public health. 2 Therefore, development of new antibiotics has become increasingly urgent.
Quinolones as the second widest used antibiotics, are mainstays of chemotherapy against various bacterial infections. 3, 4 Besides their classical antibacterial activities, quinolone derivatives also endow with various atypical biological properties such as anti-malarial, 5, 6 anti-tubercular, 7, 8 anti-tumor 9,10 and anti-HIV activities, 11 and occupy an important position in drug development.
The structure-activity relationship (SAR) revealed that substituents at C-7 position influenced the antibacterial potency, spectrum, bioavailability, solubility, safety and pharmacokinetic profiles significantly, and this position is recognized as the most adaptable site for chemical modification. 1 Moreover, incorporation of large volume substituent at C-7 position of quinolone core is not a barrier to penetration, so various biological pharmacophores have been introduced into this position. 12 Quinolone hybrids have the potential to provide novel drugs with a synergistic effect in terms of efficacy, lowered resistance selection propensity, activity against resistant bacteria, and reduced toxicity in comparison to a cocktail of the two drugs. 13, 14 Great achievements have been obtained in searching quinolone hybrids as antibacterial agents in the past three decades, as evidenced by some of them which are exemplified by Ro-23-9424 and CBR-2092 are under pre-clinical or clinical evaluations for treatment of infections caused by various clinically relevant pathogens including fluoroquinolone-resistant, multidrugresistant and difficult to treat bacteria. 1, 2 Plech et al. reported several series of ciprofloxacin-1,2,4-triazole-5(4H)-thione hybrids 1, where R 1 is phenyl and R 2 is mainly phenyl or benzyl group, respectively, and some of the hybrids were more potent than the parent ciprofloxacin against the tested pathogens. [15] [16] [17] [18] The SAR studies indicated that the substituents at C-3 position of 1,2,4-triazole-5(4H)-thione motif have great influence on the antibacterial activity, and phenyl ring is indispensable for the excellent antibacterial activity; For N-4 position of the 1,2,4triazole-5(4H)-thione moiety, the length of alkyl substituent plays a pivotal role in the antibacterial activity, and shorter alkyl substituent preferred.
The studies revealed that fluoroquinolones with 2fluorocyclopropyl at N-1 position could modulate the lipophilicity and reduce the central nervous system (CNS) toxicity, 19 and sitafloxacin with a (1R, 2S)-2fluorocyclopropyl group at the N1-position has already been approved for the treatment of various bacterial infections. 20 Inspired by the above research results, fourteen novel 1-[(1R, 2S)-2-fluorocyclopropyl] ciprofloxacin-(4-methyl-3-aryl)-1,2,4-triazole-5(4H)-thione hybrids 6a-n were designed, synthesized and evaluated for their in vitro antibacterial activities against representative Gram-positive and -negative bacteria in this study. The preliminary SAR study is also discussed to facilitate the further development of this kind of hybrids.
RESULTS AND DISCUSSION

Chemistry
The detailed synthetic route for 1-[(1R,2S)-2fluorocyclopropyl]ciprofloxacin-(4-methyl-3-aryl)-1,2,4-triazole-5(4H)-thione hybrids 6a-n is depicted in Scheme 1. [15] [16] [17] Treatment of substituted aryl hydrazides 1 with isothiocyanatomethane 2 in ethanol provided the corresponding thiosemicarbazides 3, which were subsequently cyclized in 2% NaOH solution to give the key intermediates 1,2,4-triazole-5(4H)-thiones 4. Finally, the Mannich reaction was performed with 1,2,4-triazole-5(4H)-thiones 4, 1-[(1R, 2S)-2-fluorocyclopropyl] ciprofloxacin 5 and formaldehyde in ethanol to give the titled hybrids 6a-n.
Antibacterial Activity
The 1-[(1R, 2S)-2-fluorocyclopropyl] ciprofloxacin-(4-methyl-3-aryl)-1,2,4-triazole-5(4H)-thione hybrids 6a-n were evaluated for their in vitro antibacterial activity against representative strains using standard technique. 21, 22 The minimum inhibitory concentration (MIC) is defined as the concentration of the compound required to give complete inhibition of bacterial growth, and the MIC values of 6a-n along with those of vancomycin (VAN), ciprofloxacin (CPFX), levofloxacin (LVFX) and 8-methoxy ciprofloxacin (8-OMe CPFX) and the parent 1-[(1R, 2S)-2fluorocyclopropyl] ciprofloxacin 5 for comparison, are listed in Table 1 and Table 2 , respectively.
From Table 1 and Table 2 it can be concluded that all 1-[(1R, 2S)-2-fluorocyclopropyl] ciprofloxacin-(4-methyl-3-aryl)-1,2,4-triazole-5(4H)-thione hybrids 6a-n have broad-spectrum antibacterial activity. As shown in Table 1 , all hybrids displayed promising potency in inhibiting the growth of some clinically important Grampositive pathogens such as the methicillin-sensitive Staphylococcus epidermidis (MSSE), the methicillin-sensitive S. aureus (MSSA), methicillin-resistant S. aureus (MRSA) and Enterococcus faecalis (two strains) with MIC in a range of 0.41 to 23.53 μM, which were more potent than the parent 5 (MIC: 2.86~>366.64 μM), and were no inferior to the references CPFX (MIC: 0.34~348.67 μM), LVFX (MIC: 0.35~177.22 μM) and 8-OMe CPFX (MIC: 0.35~88.61 μM). In particular, the most active hybrid 6m (MIC: 0.41~6.53 μM) was ≥1.8 folds more potent than the parent 5 against MSSE, MSSA, MRSE, MRSA and Enterococcus faecalis, could act as a lead for further optimization.
The anti-Gram-negative activity of the target hybrids presented in Table 2 revealed that all hybrids 6a-n endowed with excellent activity with MIC<1 μM against the majority of the tested Gram-negative strains. In general, their anti-Gramnegative activity was comparable to or better than the parent 5 as well as the references CPFX, LVFX and 8-OMe CPFX, and was far more potent than VAN (MIC: >88.32 μM). Amongst them, hybrid 6b as found to be most active against the tested Gramnegative pathogens, and the MICs were ≤0.05 μM against most of the tested strains. The SAR revealed that 1) pyridinyl and substituted phenyl ring at C'-3 position contributed equally to the antibacterial activity; 2) the hybrid 6e was more potent than 6d suggested that -OH at ortho-position of phenyl ring favored the activity; 3) the hybrid 6k was as potent as 6e indicated that introduction of nathphyl instead of phenyl couldn't improve the activity; 4) in general, introduction of neither electron-donating -OH and -NH 2 nor electron-withdrawing -Cl couldn't boost up the activity greatly.
EXPERIMENTAL General
Melting points were determined in open capillaries and uncorrected. 1 H-NMR spectra were determined on a Varian Mercury-400 spectrometer (Varian Medical Systems Inc., Palo Alto, CA, USA) in DMSO-d 6 using tetra-methylsilane (TMS) as an internal standard. Unless otherwise noted, the reagents were obtained from a commercial supplier and were used without further purification.
Synthesis
1 mmol of the 1,2,4-triazole-5(4H)-thiones 4 was dissolved in 40 mL of anhydrous ethanol and then fluoroquinolone 5 (1 mmol) and formaldehyde solution (aq. 37%, 1 mmol) were added. The mixture was stirred at refluxing for 10 h, and then cooled to room temperature. The precipitate was filtered off, dried, and crystallized by ethanol (10 mL) to give desired hybrids 6a-n.
Characteristics of synthesized compounds
7-(4-((4-methyl-3-(pyridin-4-yl)-5-thioxo-4,5-dihydro-1H-1, 2,4-triazol-1-yl)methyl)piperazin-1-yl)-6-fluoro-1-((1R,2S)-2-fluorocyclopropyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (6a)
Yield: 46%. M.p.: 174-176 °C. 1 ((4-methyl-3-(pyridin-2-yl)-5-thioxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)methyl)piperazin-1-yl)-6-fluoro-1-((1R,2S)-2-fluorocyclopropyl)-4-oxo-1,4-dihydroquinoline-3 6-fluoro-1-((1R,2S)-2-fluorocyclopropyl)-7-(4-((3-(3hydroxyphenyl)-4-methyl-5-thioxo-4,5-dihydro-1H-1,2,4triazol-1-yl)methyl)piperazin-1-yl)-4-oxo-1,4dihydroquinoline-3-carboxylic acid (6d 6-fluoro-1-((1R,2S)-2-fluorocyclopropyl)-7-(4-((3-(2hydroxyphenyl)-4-methyl-5-thioxo-4,5-dihydro-1H-1,2,4 7-(4-((4-methyl-3-(4-methoxyphenyl)-5-thioxo-4,5dihydro-1H-1,2,4-triazol-1-yl)methyl)piperazin-1-yl)-6fluoro-1-((1R,2S)-2-fluorocyclopropyl)-4-oxo-1,4 7-(4-((4-methyl-3-(3-methoxyphenyl)-5-thioxo-4,5dihydro-1H-1,2,4-triazol-1-yl) 7-(4-((4-methyl-3-(2-methoxyphenyl)-5-thioxo-4,5dihydro-1H-1,2,4-triazol-1-yl)methyl)piperazin-1-yl)-6fluoro-1-((1R,2S)-2-fluorocyclopropyl)-4-oxo-1,4 (4-((3-(4-chlorophenyl)-4-methyl-5-thioxo-4,5-dihydro-1H-1,2,4-triazol-1-yl) 7-(4-((3-(4-aminophenyl)-4-methyl-5-thioxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)methyl)piperazin-1-yl)-6-fluoro-1-((1R,2S)-2-fluorocyclopropyl)-4-oxo-1,4 1-((1R,2S)-2-fluorocyclopropyl)-7-(4-((3-(3,4 1-((1R,2S)-2-fluorocyclopropyl)-4-oxo-7-(4-((4methyl-5-thioxo-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-1,2,4-triazol-1-yl)methyl)piperazin-1-yl)-1,4 
7-(4-((4-methyl-3-(pyridin-3-yl)-5-thioxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)methyl)piperazin-1-yl)-6-fluoro-1-((1R,2S)-2-fluorocyclopropyl)-4-oxo-1,4dihydroquinoline-3-carboxylic acid (6b)
7-(4-
triazol-1-yl)methyl)piperazin-1-yl)-4-oxo-1,4dihydroquinoline-3-carboxylic acid (6e)
methyl)piperazin-1-yl)-6fluoro-1-((1R,2S)-2-fluorocyclopropyl)-4-oxo-1,4dihydroquinoline-3-carboxylic acid
7-
methyl)piperazin-1-yl)-6-fluoro-1-((1R,2S)-2-fluorocyclopropyl)-4-oxo-1,4dihydroquinoline-3-carboxylic acid
6-fluoro-1-((1R,2S)-2-fluorocyclopropyl)-7-(4-((3-(2hydroxynaphth-1-yl)-4-methyl-5-thioxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)methyl)piperazin-1-yl)-4-oxo-1,4dihydroquinoline-3-carboxylic acid (6k)
dimethoxyphenyl)-4-methyl-5-thioxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)methyl)piperazin-1-yl)-4-oxo-1,4dihydroquinoline-3-carboxylic acid (6l)
6-fluoro-1-((1R,2S)-2-fluorocyclopropyl)-7-(4-((3-(3,5-dimethoxyphenyl)-4-methyl-5-thioxo-4,5dihydro-1H-1,2,4-triazol-1-yl)methyl)piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (6m)
Anti-Bacterial MIC Determination
All hybrids were screened for their in vitro antibacterial activity against representative Gram-positive and Gramnegative strains, by means of standard two-fold serial dilution method using agar media [21, 22] . Hybrids (10.0 mg) were dissolved in 0.1 N NaOH solution and water (10 mL). Further progressive two folds serial dilution with melted Mueller-Hinton agar was performed to obtain the required concentrations of 128, 64, 32, 16, 8, 4, 2, 1, 0.5, 0.25, 0.125, 0.06, 0.03, 0.015 and 0.008 mg/mL. Petri dishes were incubated with 10 4 colony-forming units (cfu) and incubated at 35 °C for 18-24 h.
CONCLUSIONS
In summary, a series of novel 1-[(1R,2S)-2fluorocyclopropyl] ciprofloxacin-(4-methyl-3aryl)-1,2,4-triazole-5(4H)-thione hybrids 6a-n were designed, synthesized, and assessed for their antibacterial activity against a panel of clinically important pathogens. The results show that all of the hybrids were more potent than the parent 1-[(1R, 2S)-2-fluorocyclopropyl] ciprofloxacin 5, and were no inferior to CPFX, LVFX and 8-OMe CPFX against the majority of the tested pathogens. Moreover, the anti-Gram-negative bacteria activity of hybrids was far more potent than VAN.
